The HIV vaccine has successfully passed the final phase of clinical trials, showing immunity in 99% of patients, according to a study by Emory Institute.
During the clinical trial, two treatments were compared – the lenacapavir vaccine and the daily pills of Truvada. More than 3,000 participants took part in the trial, which was divided into two groups:
Of the 2,179 people who received the lenacapavir vaccine, only two contracted HIV. 99% of participants in this group remained HIV-free. In the group of 1,086 people taking Truvada daily, nine people contracted HIV.
Lenacapavir injections need to be administered twice a year. However, the effectiveness of daily pills significantly decreases with inconsistent use. This makes the vaccine more effective compared to taking oral medication, scientists note.
If the results of the study remain stable, the vaccine could be released to the market as early as 2025, pending approval from the U.S. Food and Drug Administration (FDA).
